Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDRX

DatePrice TargetRatingAnalyst
2/8/2024$8.00Buy
Ladenburg Thalmann
More analyst ratings

$BDRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

    MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

    February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025. The live, interactive online event will give existing shareh

    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BDRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BDRX
SEC Filings

See more

$BDRX
Leadership Updates

Live Leadership Updates

See more
  • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance
  • Biodexa Appoints Ann Merchant to the Board of Directors

    Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

    $ALVO
    $BDRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$BDRX
Financials

Live finance-specific insights

See more
  • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

    CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BDRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more